New York, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Ewing’s Sarcoma Treatment Market by Type and Geography - Global Forecast and Analysis 2019-2023" - https://www.reportlinker.com/p05821758/?utm_source=GNW
In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high efficacy of combination therapy in treating Ewing’s sarcoma will play a significant role in the combination therapy segment to maintain its market position. Also, our global Ewing’s sarcoma treatment market report looks at factors such as the growing awareness about and funding for Ewing’s sarcoma, regulatory incentives, and financial assistance programs and reimbursement schemes. However, lack of approved therapies for Ewing’s sarcoma, absence of predictive biomarkers in Ewing’s sarcoma, and side-effects of chemotherapy may hamper the growth of the Ewing’s sarcoma treatment industry over the forecast period.
Global Ewing’s Sarcoma Treatment Market: Overview
Financial assistance programs and reimbursement schemes
The increasing cost of therapeutics for the treatment of various indications is encouraging governments of various countries and pharmaceutical vendors to introduce several financial assistance programs and reimbursement schemes. There are several drug assistance programs that offer payment limitation programs for costly medications such as chemotherapeutics. GlaxoSmithKline, Merck, and Pfizer are some of the prominent vendors providing prescription drug assistance programs to patients. Such assistance programs increase the patient adherence to drug treatment which will eventually lead to the expansion of the global Ewing’s sarcoma treatment market at a CAGR of almost 6% during the forecast period.
Emergence of regenerative therapies
Regenerative medicines, including gene therapy, are gaining traction in the market. This is encouraging several pharmaceutical companies to study and develop a gene therapy to treat metastatic Ewing’s sarcoma and recurrent Ewing’s tumors. The new therapeutic methods help in minimizing tumor cell proliferation in advance Ewing’s sarcoma. For instance, Gradalis is conducting a Phase I clinical trial to evaluate pbi-shRNA EWS/FLI1 Type 1 LPX, an anti-stathmin gene therapy.The growing focus on advancing regenerative medicines in clinical phases is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global Ewing’s sarcoma treatment market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Ewing’s sarcoma treatment manufacturers, that include Amneal Pharmaceuticals Inc., Baxter International Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Also, Ewing’s sarcoma treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all future growth opportunities.
Read the full report: https://www.reportlinker.com/p05821758/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
The global Ewing's sarcoma treatment market at a CAGR of almost 6% during the forecast period
Global Ewing’s Sarcoma Treatment Market: About this market This Ewing’s sarcoma treatment market analysis considers sales from monotherapy and combination therapy types. Our study also finds the sales of Ewing’s sarcoma treatment in Asia, Europe, North America, and ROW.
| Source: ReportLinker FR